NURECA2026-04-012026-06-30NURECA2026-04-012026-06-30in-capmkt:OtherExpenses1MemberNURECA2026-04-012026-06-30in-capmkt:OtherExpenses2MemberNURECA2026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543264NURECANOTLISTEDINE0DSF01015NURECA LIMITEDMain BoardEquity2026-04-012027-03-312026-07-212026-07-14INRMillionsQuarterlyFirst quarterSingle segmentHome Healthcare and Wellness Products2026-07-2115:00:002026-07-2115:40:00Declaration of unmodified opinionfalsefalseNot Applicable2026-04-012026-06-30UnauditedStandalone40396000019180000423140000020371000067570000402700001770000566000067970000386950000361900000361900001500000103700001187000002432000000002432000002432000095420000102.552.55002.552.551. These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards (IND AS) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard) Rules, 2015, as amended and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other accounting principles generally accepted in India. <br /> <br /> 2.The Company operates in single business segment i.e. "Home healthcare and wellness products" hence there are no reportable segments as per Ind AS 108 "Operating Segments". <br /> <br /> 3. The figures for the last quarter ended March 31, 2026 is the balancing figures between audited figures in respect of the full financial year and the published, year to date, figures up to the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subject to audit. <br /> <br /> 4. During the previous year, the Company undertook a buyback of equity shares through the tender offer route. The Company bought back equity shares at a price of Rs.330 per share. The buyback was funded from the Company’s free reserves, including securities premium. The buyback was completed during the quarter ended December 31, 2025, accordingly equity shares bought back have been extinguished in accordance with applicable law and a Capital Redemption Reserve equal to the nominal value of the shares bought back has been created pursuant to Section 69 of the Companies Act, 2013. <br /> <br /> 5. During the previou year, the Company has filed Scheme of Merger by Absorption wherein and whereby Nureca Technologies Private Limited, a wholly owned subsidiary of the Company will be merged with the Company (“the Scheme of Merger”). The Scheme of Merger is effective from a proposed appointed date of April 1, 2025, subject to the sanction of the National Company Law Tribunal and other regulatory approvals. Pending sanction of the Scheme of Merger, no accounting impact has been recognized in these results. <br /> <br /> 6. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on July 21, 2026. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, has been completed by the Statutory Auditors and they have expressed an unmodified opinion on the aforesaid resultsFair value changes and net loss on investments700000Others67270000000UnauditedtrueSinghi and Companytrue2028-08-31